Skip to content

A Study on the Effects of Consuming Foods Containing Fermented Rice Bran on Bowel Movements --A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Trial--

A Study on the Effects of Consuming Foods Containing Fermented Rice Bran on Bowel Movements --A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Trial-- - A Study on the Effects of Consuming Foods Containing Fermented Rice Bran on Bowel Movements

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000060916
Enrollment
100
Registered
2026-03-13
Start date
2026-03-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intake of the active food (1 cupsule per day for 4 weeks) Intake of the placebo food (1 cupsule per day for 4 weeks)

Sponsors

TES Holdings Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy men and women aged 20 years or older but under 65 years at the time of obtaining consent to participate in the study. 2) Healthy individuals without chronic physical conditions, including skin diseases. 3) Individuals experiencing mild constipation with relatively hard stool consistency. 4) Individuals with spontaneous bowel movements approximately 3 to 5 times per week. 5) Individuals who have received sufficient explanation regarding the purpose and content of this study, possess the capacity to consent, voluntarily volunteer to participate after fully understanding, and can provide written consent to participate in this study. 6) Individuals who can attend the designated examination date and undergo the examination. 7) Individuals deemed suitable for participation in this study by the principal investigator.

Exclusion criteria

Exclusion criteria: Individuals 1) currently suffering from any disease and undergoing pharmacological treatment. 2) with a history or current presence of hemorrhoids, chronic fatigue syndrome, mental illness, sleep disorders, hypertension, diabetes, dyslipidemia, or other serious diseases. 3) with a history or current condition of serious liver, kidney, heart, lung, blood, brain, or gastrointestinal disorders. 4) diagnosed with irritable bowel syndrome or inflammatory bowel disease. 5) with periodontal disease or needing dental treatment during the study. 6) who have taken or applied medication for disease treatment within the past month. 7) who habitually take laxatives, intestinal regulators, or similar medications. 8) under treatment for functional constipation or similar conditions. 9) diagnosed with chronic constipation under the 2023 Diagnostic Guidelines for Bowel Dysfunction. 10) with severe anemia. 11) with a BMI of 30.0 kg/m2 or higher. 12) with allergies to test food components, other foods, or medications. 13) whose use of bowel-improving foods or supplements has changed or may change during the study. 14) who used functional foods containing rice bran fermented within the past 3 months. 15) with irregular eating habits or a tendency toward an unbalanced diet 16) whose average weekly pure alcohol consumption exceeds 40 g/day for men and 20 g/day for women. 17) with regular exercise habit (>=30 minutes per session, at least twice per week). 18) with smoking habits. 19) who may need allergy medication during the study. 20) with irregular lifestyles, such as shift work or night work. 21) who may alter their lifestyle habits during the study period. 22) who donated 200 mL within 1 month or 400 mL within 3 months before the study. 23) in another clinical study or within 3 months of one. 24) pregnant, breastfeeding, or planning pregnancy during the study. 25) otherwise deemed ineligible for this study by the principal investigator.

Design outcomes

Primary

MeasureTime frame
Number of bowel movements recorded in the bowel movement diary

Secondary

MeasureTime frame
*Secondary Evaluation Items 1) Number of bowel movements days per week, stool volume, stool consistency, stool odor, sensation of incomplete evacuation, sense of relief, pain, straining (as recorded in bowel movement diary) 2) Salivary assays 3) VAS questionnaire regarding quality of life (QOL) *Safety Assessment 1) Blood Pressure/Pulse 2) Weight/Body Fat Percentage/BMI 3) Physician Consultation/Assessment of Adverse Events and Side Effects 4) Daily Activity Log

Countries

Japan

Contacts

Public ContactRyoma Shimizu

TES Holdings Co., Ltd. Administrative Department of Clinical Trials

r.shimizu@tes-h.co.jp+81-3-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026